Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years

Addiction

Volumn 107, Issue 6, 2012, Pages 1174-1184

  Rössler, Wulf ^a,b   Hengartner, Michael P ^a   Angst, Jules ^a   Ajdacic Gross, Vladeta ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Alcohol; Cannabis; Epidemiology; Psychotic experiences; Schizophrenia; Subclinical psychosis; Substance abuse

Indexed keywords

ADDICTION; ADULT; ARTICLE; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; PSYCHOSIS; SCHIZOPHRENIA;

FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84860570267     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03760.x     Document Type: Article

References (40)

1. Howes O. D., Montgomery A. J., Asselin M. C., Murray R. M., Grasby P. M., Mcguire P. K. The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results. Eur Neuropsychopharmacol 2006; 16: s177.
2. Murray R. M., Lappin J., Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 2008; 18: s129-34.
3. Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia-psychopathological and behavioral correlates. Eur Psychiatry 2002; 17: 9-16.
4. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160: 13-23.
5. Baler R. D., Volkow N. D. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 2006; 12: 559-66.
6. Caton C. L., Drake R. E., Hasin D. S., Dominguez B., Shrout P. E., Samet S. etal. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry 2005; 62: 137-45.
7. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-6.
8. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T. E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-3.
9. Compton M. T., Kelley M. E., Ramsay C. E., Pringle M., Goulding S. M., Esterberg M. L. etal. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009; 166: 1251-7.
10. Degenhardt L., Hall W. D., Lynskey M., Mcgrath J., Mclaren J., Calabria B. etal. Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med 2009; 6: e1000133.
11. Kuepper R., Morrison P. D., Van Os J., Murray R. M., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res 2010; 121: 107-17.
12. Moore T. H., Zammit S., Lingford-Hughes A., Barnes T. R., Jones P. B., Burke M. etal. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
13. Smit F., Bolier L., Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004; 99: 425-30.
14. Dunn G., Pickles A., Tansella M., Vazquez-Barquero J. L. Two-phase epidemiological surveys in psychiatric research. Br J Psychiatry 1999; 174: 95-100.
15. Derogatis L. R. Symptom Checklist 90, R-Version Manual I: Scoring, Administration, and Procedures for the SCL-90. Baltimore, MD: Johns Hopkins Press; 1977.
16. Eich D., Ajdacic-Gross V., Condrau M., Huber H., Gamma A., Angst J. etal. The Zurich Study: participation patterns and Symptom Checklist 90-R scores in six interviews, 1979-99. Acta Psychiatr Scand Suppl 2003; 108: 11-4.
17. Angst J., Dobler-Mikola A., Binder J. The Zurich study-a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. I. Problem, methodology. Eur Arch Psychiatry Neurol Sci 1984; 234: 13-20.
18. Merikangas K. R., Zhang H., Avenevoli S., Acharyya S., Neuenschwander M., Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry 2003; 60: 993-1000.
19. Derogatis L. R. Symptom Checklist-90-revised. In: American Psychiatric Association, editor. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000, p. 81-4.
20. Schmitz N., Hartkamp N., Kiuse J., Franke G. H., Reister G., Tress W. The Symptom Check-List-90-R (SCL-90-R): a German validation study. Qual Life Res 2000; 9: 185-93.
21. Olsen L. R., Mortensen E. L., Bech P. The SCL-90 and SCL-90R versions validated by item response models in a Danish community sample. Acta Psychiatr Scand 2004; 110: 225-9.
22. Rossler W., Riecher-Rossler A., Angst J., Murray R., Gamma A., Eich D. etal. Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res 2007; 92: 1-14.
23. Rossler W., Angst J., Gamma A., Haker H., Stulz N., Merikangas K. R. etal. Reappraisal of the interplay between psychosis and depression symptoms in the pathogenesis of psychotic syndromes: results from a twenty-year prospective community study. Eur Arch Psychiatry Clin Neurosci 2011; 261: 11-9.
24. Rossler W., Hengartner M. P., Ajdacic-Gross V., Haker H., Gamma A., Angst J. Sub-clinical psychosis symptoms in young adults are risk factors for subsequent common mental disorders. Schizophr Res 2011; 131: 18-23.
25. Rossler W., Vetter S., Mueller M., Gallo W. T., Haker H., Kawohl W. etal. Risk factors at the low end of the psychosis continuum: much the same as at the upper end? Psychiatry Res 2011; 189: 77-81.
26. Breetvelt E. J., Boks M. P., Numans M. E., Selten J. P., Sommer I. E., Grobbee D. E. etal. Schizophrenia risk factors constitute general risk factors for psychiatric symptoms in the population. Schizophr Res 2010; 120: 184-90.
27. Spauwen J., Krabbendam L., Lieb R., Wittchen H. U., Van Os J. Sex differences in psychosis: normal or pathological? Schizophr Res 2003; 62: 45-9.
28. Faul F., Erdfelder E., Lang A.-G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-91.
29. Singer J. D., Willett J. B. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press; 2003.
30. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Rev 2000; 31: 371-84.
31. Lamarque S., Taghzouti K., Simon H. Chronic treatment with delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001; 41: 118-29.
32. Degenhardt L., Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med 2001; 31: 659-68.
33. Fergusson D. M., Horwood L. J., Swain-Campbell N. R. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33: 15-21.
34. Johns L. C., Cannon M., Singleton N., Murray R. M., Farrell M., Brugha T. etal. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 2004; 185: 298-305.
35. Mcgrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M. R. etal. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67: 440-7.
36. Jordaan G. P., Warwick J. M., Hewlett R., Emsley R. Resting brain perfusion in alcohol-induced psychotic disorder: a comparison in patients with alcohol dependence, schizophrenia and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 479-85.
37. Welch K. A., Mcintosh A. M., Job D. E., Whalley H. C., Moorhead T. W., Hall J. etal. The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophr Bull 2011; 37: 1066-76.
38. Riala K., Hakko H., Isohanni M., Pouta A., Rasanen P. Is initiation of smoking associated with the prodromal phase of schizophrenia? J Psychiatry Neurosci 2005; 30: 26-32.
39. Smith G. N., Wong H., Macewan G. W., Kopala L. C., Ehmann T. S., Thornton A. E. etal. Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophr Res 2009; 108: 258-64.
40. Barkus E., Murray R. M. Substance use in adolescence and psychosis: clarifying the relationship. Annu Rev Clin Psychol 2010; 6: 365-89.